Recent patents on emerging therapeutics for the treatment of glaucoma, age related macular degeneration and uveitis

Recent Patents on Biomedical Engineering

Volumn 5, Issue 1, 2012, Pages 83-101

  Vadlapudi, Aswani Dutt ^a   Patel, Ashaben ^a   Cholkar, Kishore ^a   Mitra, Ashim K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Age related macular degeneration (AMD); Glaucoma; Novel therapeutics; Patents; Treatment; Uveitis

Indexed keywords

AGE-RELATED MACULAR DEGENERATION; GLAUCOMA; NOVEL THERAPEUTICS; PATENTS; TREATMENT; UVEITIS;

HISTOLOGY; MOLECULES; PATENTS AND INVENTIONS; TISSUE;

OPHTHALMOLOGY;

EID: 84860289935     PISSN: 18747647     EISSN: None     Source Type: Journal    
DOI: 10.2174/1874764711205010083     Document Type: Review

References (205)

1. Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J 2010;12(3):348-60.
2. Janoria KG, Gunda S, Boddu SH, Mitra AK. Novel approaches to retinal drug delivery. Expert Opin Drug Deliv 2007;4(4):371-88.
3. Janoria KG, Hariharan S, Dasari CR, Mitra AK. Recent patents and advances in ophthalmic drug delivery. Recent Pat Drug Deliv Formul 2007;1(2):161-70.
4. Dingeldein SA, Klyce SD. Imaging of the cornea. Cornea 1988;7(3):170-82.
5. Majumdar S, Duvvuri S, Mitra AK. Membrane transporter/ receptor-targeted prodrug design: strategies for human and veterinary drug development. Adv Drug Deliv Rev 2004;56 (10): 1437-52.
6. Cunha-Vaz J. The blood-ocular barriers. Surv Ophthalmol 1979;23(5):279-96.
7. Caprioli J, Coleman AL. Blood pressure, perfusion pressure, and glaucoma. Am J Ophthalmol 2010;149(5):704-12.
8. Osborne NN. Pathogenesis of ganglion "cell death" in glaucoma and neuroprotection: focus on ganglion cell axonal mitochondria. Prog Brain Res 2008;173:339-52.
9. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90(3):262-7.
10. Quigley HA, Vitale S. Models of open-angle glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci 1997;38(1):83-91.
11. Desai PV, Caprioli J. The treatment of normal-tension glaucoma. Prog Brain Res 2008;173:195-210.
12. Shields MB. Normal-tension glaucoma: is it different from primary open-angle glaucoma? Curr Opin Ophthalmol 2008;19(2):85-8.
13. Chen J, Runyan SA, Robinson MR. Novel ocular antihypertensive compounds in clinical trials. Clin Ophthalmol 2011;5:667-77.
14. Alm A, Nilsson SF. Uveoscleral outflow--a review. Exp Eye Res 2009;88(4):760-8.
15. Fautsch MP, Johnson DH. Aqueous humor outflow: what do we know? Where will it lead us? Invest Ophthalmol Vis Sci 2006;47 (10): 4181-7.
16. Bahrami H. Causal inference in primary open angle glaucoma: specific discussion on intraocular pressure. Ophthalmic Epidemiol 2006;13(4):283-9.
17. Coakes RL, Brubaker RF. The mechanism of timolol in lowering intraocular pressure. In the normal eye. Arch Ophthalmol 1978;96(11):2045-8.
18. Battershill PE, Sorkin EM. Ocular metipranolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in glaucoma and ocular hypertension. Drugs 1988;36(5):601-15.
19. Wandel T, Charap AD, Lewis RA, Partamian L, Cobb S, Lue JC, et al. Glaucoma treatment with once-daily levobunolol. Am J Ophthalmol 1986;101(3):298-304.
20. Kaiserman I, Fendyur A, Vinker S. Topical beta blockers in asthmatic patients-is it safe? Curr Eye Res 2009;34(7):517-22.
21. Nieminen T, Uusitalo H, Turjanmaa V, Bjarnhall G, Hedenstrom H, Maenpaa J, et al. Association between low plasma levels of ophthalmic timolol and haemodynamics in glaucoma patients. Eur J Clin Pharmacol 2005;61(5-6):369-74.
22. Harris LS, Shimmyo M, Mittag TW. Cholinesterases and contractility of cat irides. Effect of echothiophate iodide. Arch Ophthalmol 1973;89(1):49-51.
23. Mills RP, Janz NK, Wren PA, Guire KE. Correlation of visual field with quality-of-life measures at diagnosis in the Collaborative Initial Glaucoma Treatment Study (CIGTS). J Glaucoma 2001; 10(3):192-8.
24. Naveh-Floman N, Stahl V, Korczyn AD. Effect of pilocarpine on intraocular pressure in ocular hypertensive subjects. Ophthalmic Res 1986;18(1):34-7.
25. Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7(2):168-81.
26. Hollo G, Chiselita D, Petkova N, Cvenkel B, Liehneova I, Izgi B, et al. The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open-angle glaucoma. Eur J Ophthalmol 2006;16(6):816-23.
27. Stewart WC, Day DG, Stewart JA, Holmes KT, Jenkins JN. Shortterm ocular tolerability of dorzolamide 2% and brinzolamide 1% vs placebo in primary open-angle glaucoma and ocular hypertension subjects. Eye (Lond) 2004;18(9):905-10.
28. Silver LH. Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies. Brinzolamide Comfort Study Group. Surv Ophthalmol 2000;44 Suppl 2:S141-5.
29. Silver LH. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group. Am J Ophthalmol 1998;126(3):400-8.
30. O'Connor DJ, Martone JF, Mead A. Additive intraocular pressure lowering effect of various medications with latanoprost. Am J Ophthalmol 2002;133(6):836-7.
31. Burke J, Schwartz M. Preclinical evaluation of brimonidine. Surv Ophthalmol 1996;41 Suppl 1:S9-18.
32. Rahman MQ, Ramaesh K, Montgomery DM. Brimonidine for glaucoma. Expert Opin Drug Saf 2010;9(3):483-91.
33. Schmier JK, Covert DW, Robin AL. First-year treatment costs among new initiators of topical prostaglandin analog identified from November 2007 through April 2008. Curr Med Res Opin 2010;26(12):2769-77.
34. Sharif NA, Kelly CR, Crider JY. Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues. Invest Ophthalmol Vis Sci 2003;44(2):715-21.
35. Hellberg MR, Sallee VL, McLaughlin MA, Sharif NA, Desantis L, Dean TR, et al. Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. J Ocul Pharmacol Ther 2001;17(5):421-32.
36. Cantor LB. Clinical pharmacology of bimatoprost. Expert Opin Drug Metab Toxicol 2005;1(1):151-7.
37. Krauss AH, Woodward DF. Update on the mechanism of action of bimatoprost: a review and discussion of new evidence. Surv Ophthalmol 2004;49 Suppl 1:S5-11.
38. Woodward DF, Krauss AH, Chen J, Lai RK, Spada CS, Burk RM, et al. The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol 2001;45 Suppl 4:S337-45.
39. Sharif NA, Kelly CR, Williams GW. Bimatoprost (Lumigan(R) is an agonist at the cloned human ocular FP prostaglandin receptor: real-time FLIPR-based intracellular Ca(2+) mobilization studies. Prostaglandins Leukot Essent Fatty Acids 2003;68(1):27-33.
40. Maxey KM, Johnson JL, LaBrecque J. The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist. Surv Ophthalmol 2002;47 Suppl 1:S34-40.
41. Sharif NA, Williams GW, Kelly CR. Bimatoprost and its free acid are prostaglandin FP receptor agonists. Eur J Pharmacol 2001;432 (2-3):211-3.
42. Bahler CK, Howell KG, Hann CR, Fautsch MP, Johnson DH. Prostaglandins increase trabecular meshwork outflow facility in cultured human anterior segments. Am J Ophthalmol 2008;145 (1):114-9.
43. Hylton C, Robin AL. Update on prostaglandin analogs. Curr Opin Ophthalmol 2003;14(2):65-9.
44. Gaton DD, Sagara T, Lindsey JD, Gabelt BT, Kaufman PL, Weinreb RN. Increased matrix metalloproteinases 1, 2, and 3 in the monkey uveoscleral outflow pathway after topical prostaglandin F(2 alpha)-isopropyl ester treatment. Arch Ophthalmol 2001;119 (8):1165-70.
45. Walters TR, DuBiner HB, Carpenter SP, Khan B, VanDenburgh AM. 24-Hour IOP control with once-daily bimatoprost, timolol gelforming solution, or latanoprost: a 1-month, randomized, comparative clinical trial. Surv Ophthalmol 2004;49 Suppl 1:S26-35.
46. Hellberg MR, McLaughlin MA, Sharif NA, DeSantis L, Dean TR, Kyba EP, et al. Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist. Surv Ophthalmol 2002;47 Suppl 1:S13-33.
47. Netland PA, Landry T, Sullivan EK, Andrew R, Silver L, Weiner A, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132(4):472-84.
48. Grierson I, Millar L, De Yong J, Day J, McKechnie NM, Hitchins C, et al. Investigations of cytoskeletal elements in cultured bovine meshwork cells. Invest Ophthalmol Vis Sci 1986;27(9):1318-30.
49. Lee AJ, Goldberg I. Emerging drugs for ocular hypertension. Expert Opin Emerg Drugs 2011;16(1):137-61.
50. Pollard TD, Cooper JA. Actin, a central player in cell shape and movement. Science 2009;326(5957):1208-12.
51. Ethier CR, Read AT, Chan DW. Effects of latrunculin-B on outflow facility and trabecular meshwork structure in human eyes. Invest Ophthalmol Vis Sci 2006;47(5):1991-8.
52. Sabanay I, Tian B, Gabelt BT, Geiger B, Kaufman PL. Latrunculin B effects on trabecular meshwork and corneal endothelial morphology in monkeys. Exp Eye Res 2006;82(2):236-46.
53. Peterson JA, Tian B, McLaren JW, Hubbard WC, Geiger B, Kaufman PL. Latrunculins' effects on intraocular pressure, aqueous humor flow, and corneal endothelium. Invest Ophthalmol Vis Sci 2000;41(7):1749-58.
54. Okka M, Tian B, Kaufman PL. Effects of latrunculin B on outflow facility, intraocular pressure, corneal thickness, and miotic and accommodative responses to pilocarpine in monkeys. Trans Am Ophthalmol Soc 2004;102:251-7; discussion 7-9.
55. Tian B, Gabelt BT, Geiger B, Kaufman PL. The role of the actomyosin system in regulating trabecular fluid outflow. Exp Eye Res 2009;88(4):713-7.
56. Hall A. Rho GTPases and the control of cell behaviour. Biochem Soc Trans 2005;33(Pt 5):891-5.
57. Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 2003;4(6):446-56.
58. Olson MF. Applications for ROCK kinase inhibition. Curr Opin Cell Biol 2008;20(2):242-8.
59. Strutton DR, Walt JG. Trends in glaucoma surgery before and after the introduction of new topical glaucoma pharmacotherapies. J Glaucoma 2004;13(3):221-6.
60. Rao VP, Epstein DL. Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma. BioDrugs 2007;21(3):167-77.
61. Nakajima E, Nakajima T, Minagawa Y, Shearer TR, Azuma M. Contribution of ROCK in contraction of trabecular meshwork: proposed mechanism for regulating aqueous outflow in monkey and human eyes. J Pharm Sci 2005;94(4):701-8.
62. Fukiage C, Mizutani K, Kawamoto Y, Azuma M, Shearer TR. Involvement of phosphorylation of myosin phosphatase by ROCK in trabecular meshwork and ciliary muscle contraction. Biochem Biophys Res Commun 2001;288(2):296-300.
63. Jacobs M, Hayakawa K, Swenson L, Bellon S, Fleming M, Taslimi P, et al. The structure of dimeric ROCK I reveals the mechanism for ligand selectivity. J Biol Chem 2006;281(1):260-8.
64. Mueller BK, Mack H, Teusch N. Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov 2005;4 (5):387-98.
65. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol 1998; 126 (4):487-97.
66. Tokushige H, Inatani M, Nemoto S, Sakaki H, Katayama K, Uehata M, et al. Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys. Invest Ophthalmol Vis Sci 2007;48 (7):3216-22.
67. DeLong MA SJ, Royalty SM, et al. Discovery and in vitro SAR of AR-12286, a potent kinase inhibitor for the treatment of glaucoma. In: 240th American Chemical Society National Meeting, 2010 August 22-26; Boston, MA, US.
68. Wang R-F SJ, Kopczynski C. Effect of 0.6% AR-12286 on aqueous humor dynamics in 6 normotensive monkey eyes. In: ARVO E-Abstract 1465, 2009.
69. Mizuno K, Koide T, Fujieda Y, Mori J, Kondo S-I, Matsumoto J, et al. Ocular Hypotensive and Neuroprotective Effects of K-115, a Novel Rho-Kinase Inhibitor. Invest. Ophthalmol. Vis. Sci. 2007;48 (5):4805.
70. Karl MO, Peterson-Yantorno K, Civan MM. Cell-specific differential modulation of human trabecular meshwork cells by selective adenosine receptor agonists. Exp Eye Res 2007;84 (1): 126-34.
71. Fleischhauer JC, Mitchell CH, Stamer WD, Karl MO, Peterson-Yantorno K, Civan MM. Common actions of adenosine receptor agonists in modulating human trabecular meshwork cell transport. J Membr Biol 2003;193(2):121-36.
72. Fredholm BB. Adenosine receptors as drug targets. Exp Cell Res 2010;316(8):1284-8.
73. Fredholm BB, AP IJ, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001;53(4): 527-52.
74. Kim N CC, Lam T, et al. INO-8875, an adenosine A1 agonist, lowers intraocular pressure through the conventional outflow pathway. Invest Ophthalmol Vis Sci 2010;51(ARVO E-Abstract 3238).
75. Webb RL, Sills MA, Chovan JP, Peppard JV, Francis JE. Development of tolerance to the antihypertensive effects of highly selective adenosine A2a agonists upon chronic administration. J Pharmacol Exp Ther 1993;267(1):287-95.
76. Avni I, Garzozi HJ, Barequet IS, Segev F, Varssano D, Sartani G, et al. Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial. Ophthalmology 2010;117(7):1287-93.
77. Gessi S, Merighi S, Varani K, Leung E, Mac Lennan S, Borea PA. The A3 adenosine receptor: an enigmatic player in cell biology. Pharmacol Ther 2008;117(1):123-40.
78. Okamura T, Kurogi Y, Hashimoto K, Sato S, Nishikawa H, Kiryu K, et al. Structure-activity relationships of adenosine A3 receptor ligands: new potential therapy for the treatment of glaucoma. Bioorg Med Chem Lett 2004;14(14):3775-9.
79. thEdition. Br J Pharmacol 2009;158 Suppl 1:S1-254.
80. Nichols DE, Nichols CD. Serotonin receptors. Chem Rev 2008; 108(5):1614-41.
81. May JA, McLaughlin MA, Sharif NA, Hellberg MR, Dean TR. Evaluation of the ocular hypotensive response of serotonin 5-HT1A and 5-HT2 receptor ligands in conscious ocular hypertensive cynomolgus monkeys. J Pharmacol Exp Ther 2003;306(1):301-9.
82. Gabelt BT, Millar CJ, Kiland JA, Peterson JA, Seeman JL, Kaufman PL. Effects of serotonergic compounds on aqueous humor dynamics in monkeys. Curr Eye Res 2001;23(2):120-7.
83. Gabelt BT, Okka M, Dean TR, Kaufman PL. Aqueous humor dynamics in monkeys after topical R-DOI. Invest Ophthalmol Vis Sci 2005;46(12):4691-6.
84. Allen JA, Yadav PN, Roth BL. Insights into the regulation of 5-HT2A serotonin receptors by scaffolding proteins and kinases. Neuropharmacology 2008;55(6):961-8.
85. Gray JA, Roth BL. Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists. Brain Res Bull 2001;56(5):441-51.
86. Bunch TJ SJ, Gabelt BT, et al. BVT.28949 as a potential ocular hypotensive agent in monkeys. Invest Ophthalmol Vis Sci 2004;45(ARVO E-Abstract 5040).
87. Tomida I, Pertwee RG, Azuara-Blanco A. Cannabinoids and glaucoma. Br J Ophthalmol 2004;88(5):708-13.
88. Chien FY, Wang RF, Mittag TW, Podos SM. Effect of WIN 55212-2, a cannabinoid receptor agonist, on aqueous humor dynamics in monkeys. Arch Ophthalmol 2003;121(1):87-90.
89. Shepard. AR, Clark. AF, Klimko. PG, Wax. MB. Complement C1Q Inhibitors For The Prevention And Treatment Of Glaucoma. US20090117098. 2009.
90. Park M-G, Kwak T. Pharmaceutical composition for the treatment and prevention of glaucoma. US20110020448. 2011.
91. Clark AF, Wang W-h, Mcnatt LG, Chatterton JE. RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma US7947660 2011.
92. Hellberg MR. Statins for the treatment of ocular hypertension and glaucoma. US20110098314. 2011.
93. Dantanarayana AP, May JA. Pyrazolo[3,4-e]benzoxazoles for the treatment of glaucoma US20060069096 2006.
94. Dantanarayana AP, May JA. Substituted 1-alkylamino-1Hindazoles for the treatment of glaucoma US7338972 2008.
95. Dantanarayana AP, May JA. Substituted furo[2,3-g]indazoles for the treatment of glaucoma. US07476687 2009.
96. Friedman DS, O'Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122(4):564-72.
97. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992; 99 (6):933-43.
98. Cook HL, Patel PJ, Tufail A. Age-related macular degeneration: diagnosis and management. Br Med Bull 2008;85:127-49.
99. Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. Surv Ophthalmol 1988;32(6):375-413.
100. Ayoub T, Patel N. Age-related macular degeneration. J R Soc Med 2009;102(2):56-61.
101. Bourla DH, Young TA. Age-related macular degeneration: a practical approach to a challenging disease. J Am Geriatr Soc 2006;54(7):1130-5.
102. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 1991;109 (8): 1109-14.
103. Laser photocoagulation of subfoveal neovascular lesions of agerelated macular degeneration. Updated findings from two clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 1993;111(9):1200-9.
104. Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol 1991; 109(9):1232-41.
105. Laser photocoagulation of subfoveal neovascular lesions in agerelated macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol 1991; 109 (9):1220-31.
106. Augustin AJ, Scholl S, Kirchhof J. Treatment of neovascular agerelated macular degeneration: Current therapies. Clin Ophthalmol 2009;3:175-82.
107. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001;131(5):541-60.
108. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of agerelated macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 1999;117(10):1329-45.
109. Waisbourd M, Loewenstein A, Goldstein M, Leibovitch I. Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration. Drugs Aging 2007; 24 (8):643-62.
110. Ng EW, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol 2005;40(3):352-68.
111. Gragoudas ES, Adamis AP, Cunningham ET, Jr., Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351(27):2805-16.
112. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular agerelated macular degeneration. N Engl J Med 2006;355(14):1432-44.
113. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1419-31.
114. Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006;142(1):1-9.
115. Wang Y, Wang VM, Chan CC. The role of anti-inflammatory agents in age-related macular degeneration (AMD) treatment. Eye (Lond) 2011;25(2):127-39.
116. Heier JS, Boyer DS, Ciulla TA, Ferrone PJ, Jumper JM, Gentile RC, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 2006;124(11):1532-42.
117. Aggio FB, Farah ME, Meirelles RL, Costa RA, Monteiro ML. New stratusoct findings in extrapapillary excavated anomaly and secondary macular complications. Retina 2007;27(1):113-5.
118. Emerson MV, Lauer AK. Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema. BioDrugs 2007;21(4):245-57.
119. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002;99(17):11393-8.
120. Reich SJ, Fosnot J, Kuroki A, Tang W, Yang X, Maguire AM, et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 2003;9:210-6.
121. Brucker A. Small interfering rna (CAND5) for the treatment of subfoveal choroidal neovascularization due to age-related macular degeneration. In: Retina society. Combined Retina Society/Gonin Society Meeting, 2006 Oct 15-20; Cape Town.
122. Emerson MV, Lauer AK. Current and emerging therapies for the treatment of age-related macular degeneration. Clinical ophthalmology 2008;2(2):377-88.
123. Shen J, Samul R, Silva RL, Akiyama H, Liu H, Saishin Y, et al. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther 2006;13(3):225-34.
124. Maier P, Unsoeld AS, Junker B, Martin G, Drevs J, Hansen LL, et al. Intravitreal injection of specific receptor tyrosine kinase inhibitor PTK787/ZK222 584 improves ischemia-induced retinopathy in mice. Graefes Arch Clin Exp Ophthalmol 2005;243 (6):593-600.
125. Mori K, Gehlbach P, Ando A, McVey D, Wei L, Campochiaro PA. Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2002;43(7):2428-34.
126. Steele FR, Chader GJ, Johnson LV, Tombran-Tink J. Pigment epithelium-derived factor: neurotrophic activity and identification as a member of the serine protease inhibitor gene family. Proc Natl Acad Sci U S A 1993;90(4):1526-30.
127. Wong WT, Kam W, Cunningham D, Harrington M, Hammel K, Meyerle CB, et al. Treatment of geographic atrophy by the topical administration of OT-551: results of a phase II clinical trial. Invest Ophthalmol Vis Sci 2010;51(12):6131-9.
128. Augustin A. Anecortave acetate in the treatment of age-related macular degeneration. Clin Interv Aging 2006;1(3):237-46.
129. Howard AN, Landrum JT, Bone RA. Mesozeaxanthin formulations for treatment of retinal disorders US6329432. 2001.
130. Marcus DM, Chu CK. Methods and Compositions for Treatment of Macular and Retinal Disease. US7259180. 2007.
131. Inana G, McLaren M. Methods and compositions for detecting and treating retinal diseases. US7309487. 2007.
132. Ambati J. Methods And Compositions For The Treatment Of Ocular Neovascularization. US20080299130. 2008.
133. Tamaki Y, Tahara H. Vaccine therapy for choroidal neovascularization. US20100297157 2010.
134. Caspi RR. Mechanisms underlying autoimmune uveitis. Drug Discov. Today: Dis. Mech. 2006;3:199-206.
135. Chang JH, McCluskey PJ, Wakefield D. Acute anterior uveitis and HLA-B27. Surv Ophthalmol 2005;50(4):364-88.
136. Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology 2004;111(3):491-500; discussion
137. McCannel CA, Holland GN, Helm CJ, Cornell PJ, Winston JV, Rimmer TG. Causes of uveitis in the general practice of ophthalmology. UCLA Community-Based Uveitis Study Group. Am J Ophthalmol 1996;121(1):35-46.
138. Weiner A, BenEzra D. Clinical patterns and associated conditions in chronic uveitis. Am J Ophthalmol 1991;112(2):151-8.
139. London NJ, Hovakimyan A, Cubillan LD, Siverio Jr CD, Cunningham Jr ET. Prevalence, clinical characteristics, and causes of vision loss in patients with ocular toxoplasmosis. Eur J Ophthalmol 2011.
140. Ossewaarde-van Norel A, Rothova A. Clinical review: Update on treatment of inflammatory macular edema. Ocul Immunol Inflamm 2011;19(1):75-83.
141. Nakao S, Hata Y, Miura M, Noda K, Kimura YN, Kawahara S, et al. Dexamethasone inhibits interleukin-1beta-induced corneal neovascularization: role of nuclear factor-kappaB-activated stromal cells in inflammatory angiogenesis. Am J Pathol 2007;171(3): 1058-65.
142. Bostrom BC, Sensel MR, Sather HN, Gaynon PS, La MK, Johnston K, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 2003;101(10):3809-17.
143. Urban RC, Jr., Cotlier E. Corticosteroid-induced cataracts. Surv Ophthalmol 1986;31(2):102-10.
144. Becker B, Mills DW. Elevated Intraocular Pressure Following Corticosteroid Eye Drops. JAMA 1963;185:884-6.
145. Simonini G, Cantarini L, Bresci C, Lorusso M, Galeazzi M, Cimaz R. Current therapeutic approaches to autoimmune chronic uveitis in children. Autoimmun Rev 2010;9(10):674-83.
146. Raizman MB, Donnenfeld ED, Weinstein AJ. Clinical comparison of two topical prednisolone acetate 1% formulations in reducing inflammation after cataract surgery. Curr Med Res Opin 2007;23(10):2325-31.
147. Chavan SB, Cummings EJ. An initial evaluation of (aristocort) triamcinolone and its acetonide derivative in the therapy of ocular inflammation. Part II. Clinical studies. Am J Ophthalmol 1960;49:516-30.
148. Chavan SB, Cummings EJ. An initial evaluation of (aristocort) triamcinolone in the therapy of ocular inflammation. Part I: Experimental studies. Am J Ophthalmol 1960;49:55-64.
149. Scholes GN, O'Brien WJ, Abrams GW, Kubicek MF. Clearance of triamcinolone from vitreous. Arch Ophthalmol 1985;103(10):1567-9.
150. Schindler RH, Chandler D, Thresher R, Machemer R. The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol 1982;93 (4):415-7.
151. Tano Y, Sugita G, Abrams G, Machemer R. Inhibition of intraocular proliferations with intravitreal corticosteroids. Am J Ophthalmol 1980;89(1):131-6.
152. Graham RO, Peyman GA. Intravitreal injection of dexamethasone. Treatment of experimentally induced endophthalmitis. Arch Ophthalmol 1974;92(2):149-54.
153. Habot-Wilner Z, Sallam A, Pacheco PA, Do HH, McCluskey P, Lightman S. Intravitreal triamcinolone acetonide as adjunctive treatment with systemic therapy for uveitic macular edema. Eur J Ophthalmol 2010;21(S6):56-61.
154. Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009;127 (9):1115-28.
155. Dyer D, Callanan D, Bochow T, Abraham P, Lambert HM, Lee SY, et al. Clinical evaluation of the safety and efficacy of preservative-free triamcinolone (triesence [triamcinolone acetonide injectable suspension] 40 mg/ml) for visualization during pars plana vitrectomy. Retina 2009;29(1):38-45.
156. Jaffe GJ, Yang CH, Guo H, Denny JP, Lima C, Ashton P. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci 2000;41(11): 3569-75.
157. Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006;113(6):1020-7.
158. Jaffe GJ. Reimplantation of a fluocinolone acetonide sustained drug delivery implant for chronic uveitis. Am J Ophthalmol 2008;145(4):667-75.
159. Noble S, Goa KL. Loteprednol etabonate: clinical potential in the management of ocular inflammation. BioDrugs 1998;10(4):329-39.
160. Howes JF. Loteprednol etabonate: a review of ophthalmic clinical studies. Pharmazie 2000;55(3):178-83.
161. Bartlett JD, Horwitz B, Laibovitz R, Howes JF. Intraocular pressure response to loteprednol etabonate in known steroid responders. J Ocul Pharmacol 1993;9(2):157-65.
162. Comstock TL, Paterno MR, Singh A, Erb T, Davis E. Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery. Clin Ophthalmol 2011;5:177-86.
163. Kim EC, Foster CS. Immunomodulatory therapy for the treatment of ocular inflammatory disease: evidence-based medicine recommendations for use. Int Ophthalmol Clin 2006;46(2):141-64.
164. Farber S, Diamond LK. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroylglutamic acid. N Engl J Med 1948;238(23):787-93.
165. Taylor SR, Habot-Wilner Z, Pacheco P, Lightman SL. Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema. Ophthalmology 2009;116(4):797-801.
166. Yazici H, Pazarli H, Barnes CG, Tuzun Y, Ozyazgan Y, Silman A, et al. A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med 1990;322(5):281-5.
167. Mathews JD, Crawford BA, Bignell JL, Mackay IR. Azathioprine in active chronic iridocyclitis. A double-blind controlled trial. Br J Ophthalmol 1969;53(5):327-30.
168. Lipsky JJ. Mycophenolate mofetil. The Lancet 1996;348(9038): 1357-9.
169. Morris RE, Hoyt EG, Murphy MP, Eugui EM, Allison AC. Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T-and B-cell purine synthesis. Transplant Proc 1990;22(4):1659-62.
170. Baltatzis S, Tufail F, Yu EN, Vredeveld CM, Foster CS. Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology 2003;110(5):1061-5.
171. Vitale AT, Rodriguez A, Foster CS. Low-dose cyclosporin A therapy in treating chronic, noninfectious uveitis. Ophthalmology 1996;103(3):365-73; discussion 73-4.
172. Nussenblatt RB, Palestine AG, Chan CC. Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol 1983;96(3):275-82.
173. Nussenblatt RB, Rodrigues MM, Salinas-Carmona MC, Gery I, Cevario S, Wacker W. Modulation of experimental autoimmune uveitis with cyclosporin A. Arch Ophthalmol 1982;100(7):1146-9.
174. Liu J. FK506 and ciclosporin: molecular probes for studying intracellular signal transduction. Trends Pharmacol Sci 1993;14 (5):182-8.
175. Mathews D, Mathews J, Jones NP. Low-dose cyclosporine treatment for sight-threatening uveitis: efficacy, toxicity, and tolerance. Indian J Ophthalmol 2010;58(1):55-8.
176. Isnard Bagnis C, Tezenas du Montcel S, Beaufils H, Jouanneau C, Jaudon MC, Maksud P, et al. Long-term renal effects of low-dose cyclosporine in uveitis-treated patients: follow-up study. J Am Soc Nephrol 2002;13(12):2962-8.
177. Peters DH, Fitton A, Plosker GL, Faulds D. Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 1993;46(4):746-94.
178. Friemann S, Feuring E, Padberg W, Ernst W. Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus. Transplant Proc 1998;30(4):1240-2.
179. Textor SC, Wiesner R, Wilson DJ, Porayko M, Romero JC, Burnett JC, Jr., et al. Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. Transplantation 1993;55(6):1332-9.
180. Hogan AC, McAvoy CE, Dick AD, Lee RW. Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology 2007;114(5):1000-6.
181. Stahl A, Paschek L, Martin G, Gross NJ, Feltgen N, Hansen LL, et al. Rapamycin reduces VEGF expression in retinal pigment epithelium (RPE) and inhibits RPE-induced sprouting angiogenesis in vitro. FEBS Lett 2008;582(20):3097-102.
182. Salzmann J, Lightman S. The potential of newer immunomodulating drugs in the treatment of uveitis: a review. BioDrugs 2000;13(6):397-408.
183. Terada N, Lucas JJ, Szepesi A, Franklin RA, Domenico J, Gelfand EW. Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late G1 phase of the cycle. J Cell Physiol 1993;154(1):7-15.
184. Shanmuganathan VA, Casely EM, Raj D, Powell RJ, Joseph A, Amoaku WM, et al. The efficacy of sirolimus in the treatment of patients with refractory uveitis. Br J Ophthalmol 2005;89(6):666-9.
185. Roda Perez E. [Nitrogen mustard therapy of uveitis of unknown etiology]. Rev Clin Esp 1952;44(3):173-80.
186. Okada AA. Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature. Ocul Immunol Inflamm 2005;13(5):335-51.
187. Hemady R, Tauber J, Foster CS. Immunosuppressive drugs in immune and inflammatory ocular disease. Surv Ophthalmol 1991;35(5):369-85.
188. Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum 2010;62(1):9-21.
189. Larson T, Nussenblatt RB, Sen HN. Emerging drugs for uveitis. Expert Opin Emerg Drugs 2011;16(2):309-22.
190. Leah E. Therapy: Anti-inflammatory hope for AIN457. Nat Rev Rheumatol 2010;6(12):675.
191. Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010;2(52):52ra72.
192. Heiligenhaus A, Thurau S, Hennig M, Grajewski RS, Wildner G. Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease. Graefes Arch Clin Exp Ophthalmol 2010;248(11):1531-51.
193. Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs 2011;3(1):76-99.
194. Man HW, Schafer P, Wong LM, Patterson RT, Corral LG, Raymon H, et al. Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor. J Med Chem 2009;52(6):1522-4.
195. Aspeslet L, Freitag D, Trepanier D, Abel M, Naicker S, Kneteman N, et al. ISA(TX)247: a novel calcineurin inhibitor. Transplant Proc 2001;33(1-2):1048-51.
196. Cunningham MA, Austin BA, Li Z, Liu B, Yeh S, Chan CC, et al. LX211 (voclosporin) suppresses experimental uveitis and inhibits human T cells. Invest Ophthalmol Vis Sci 2009;50(1):249-55.
197. Anglade E, Aspeslet LJ, Weiss SL. A new agent for the treatment of noninfectious uveitis: rationale and design of three LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to Treatment) trials of steroid-sparing voclosporin. Clin Ophthalmol 2008;2(4):693-702.
198. Furrer E, Berdugo M, Stella C, Behar-Cohen F, Gurny R, Feige U, et al. Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye. Invest Ophthalmol Vis Sci 2009;50(2):771-8.
199. Ottiger M, Thiel MA, Feige U, Lichtlen P, Urech DM. Efficient intraocular penetration of topical anti-TNF-alpha single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer. Invest Ophthalmol Vis Sci 2009;50(2):779-86.
200. Dhimolea E. Canakinumab. MAbs 2010;2(1):3-13.
201. Wannamaker MW, Davies RJ. Prodrug of an ice inhibitor US20090012149. 2009.
202. Groneberg R, Burges LE, Harvey D, Laird E, Munson MC, Rizzi JP, et al. Kinase Inhibitors And Methods Of Use Thereof. US20110124878. 2011.
203. Cowden WB, Bartell GJ, Eschler BM, March DR, Robertson A. Mannose-6-phosphonate compounds for the treatment of inflammatory diseases. US7648966. 2010.
204. De Matos MN, Romao CC. Methods for treating inflammatory disease by administering aldehydes and derivatives thereof. US7968605. 2011.
205. Matier WL, Patil G. Amelioration of cataracts, macular degeneration and other ophthalmic diseases. US7825134. 2010